Matthew Herper, STAT

Matthew Herper

STAT

New York, NY, United States

Contact Matthew

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • STAT
Past:
  • CNBC
  • Forbes

Recent articles by Matthew:

Moderna data suggests new Covid booster is more effective against Omicron variants

Moderna said its new booster appears to be more effective against Omicron variants than its original vaccine, and that it also seems effective against a new worrisome variant, BQ1.1. → Read More

Biogen’s new CEO, clear-eyed about company’s challenges, prepares to take the reins

“I’m not the type of guy to go run something that is smoothly running,” said Biogen's new CEO, Christopher Viehbacher. → Read More

Biogen appoints former Sanofi executive Christopher Viehbacher as CEO

Biogen named Christopher Viehbacher, who formerly ran the French drug giant Sanofi, as its new CEO on Thursday. → Read More

For its first two medicines, EQRx abandons its bold strategy to lower drug prices

EQRx, a company founded to upend the costly U.S. system for pricing new drugs, said it would abandon that goal for the two products that are closest to the market. → Read More

J&J’s Mammen out of the running for Biogen CEO post

Biogen is mulling new options in its search for a CEO after talks with a senior research executive from Johnson & Johnson reached an impasse, STAT has learned. → Read More

A live chat about 'biology's century'

CRISPR, gene therapy, CAR-T, and Covid vaccines. Science is advancing at a blistering pace. Join STAT's Matthew Herper for a live chat Monday to talk about it. → Read More

Here’s why we’re not prepared for the next wave of biotech innovation

This is "biology's century," @matthewherper writes. But we’re approaching a moment when changes in what we understand are every bit as terrifying as exhilarating. → Read More

Pfizer says vaccine to prevent RSV in newborns is effective

Pfizer’s maternal vaccine against the respiratory syncytial virus reduced the rate of severe illness in newborns by 81.8%, the company said Tuesday, meeting the goal of a pivotal study. → Read More

Josh Bilenker's last biotech sold for $8 billion. His next one is cloaked in mystery but loaded with money

The big fundraising effort by Josh Bilenker and Jeffrey Engelman is likely to seed even more curiosity about what, exactly, is happening at their new company, Treeline. → Read More

Flush with cash from Covid-19 vaccine, BioNTech founders have outsized ambitions

After the Covid-19 vaccine, BioNTech founders Ugur Sahin and Ozlem Tureci want to create a new kind of drug company. → Read More

Merck touts positive results on key drug from $11.5 billion Acceleron merger

The results for a drug to treat pulmonary arterial hypertension is considered one of the most important pipeline readouts for Merck this year. → Read More

Biogen CEO search focuses on scientists, with former J&J exec as a leading candidate

A senior researcher who was most recently at Johnson & Johnson has emerged as a top candidate to be Biogen’s CEO, according to people familiar with the discussions. → Read More

If a new Alzheimer’s drug works, was there any point to the Aduhelm controversy? Yes

If a new Alzheimer’s drug works, was there any point to the Aduhelm controversy? Yes. → Read More

Virtual Event: When the Barrier to a Breakthrough Drug Is You Can’t Make It

Join STAT to hear how developers have approached different aspects of the manufacturing process to bring new and innovative treatments to patients. → Read More

At a fashion show for people with spinal muscular atrophy, models take back their own stories

At a fashion show for people with spinal muscular atrophy, models take back their own stories. → Read More

Don’t let shrill debates keep you from getting a Covid booster

The social media-driven cacophony over Covid boosters risks drowning out the most important message about them: quite simply, that most people should get one right now. → Read More

Relay Therapeutics drug shows promise in early trial

A daily dose of Relay Therapeutics’ experimental drug for cholangiocarcinoma, a rare cancer, led to tumor shrinkage of a third or more in 15 of 17 patients with metastatic disease, the company said Wednesday. → Read More

Why Illumina has a merger mess of its own making

For Illumina, the leading maker of DNA sequencing equipment, there was bad news and worse news Tuesday. → Read More

Your questions on the new Covid vaccine boosters answered

Here's what you need to know about the new Covid-19 boosters coming to pharmacies and doctors offices. → Read More

FDA authorizes Pfizer and Moderna Covid boosters targeted against Omicron strains

The FDA authorized new Covid booster shots from Moderna and Pfizer that more closely match the strains of the coronavirus that are currently circulating in the U.S. → Read More